Rare Orbital Infections ~ State of the Art ~ Part II.

about

Rare Orbital Infections ~ State of the Art ~ Part II.

Item

http://www.wikidata.org/entity/Q54222905

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Rare Orbital Infections ~ State of the Art ~ Part II.

@en

Rare Orbital Infections ~ State of the Art ~ Part II.

@nl

type

Item

label

Rare Orbital Infections ~ State of the Art ~ Part II.

@en

Rare Orbital Infections ~ State of the Art ~ Part II.

@nl

prefLabel

Rare Orbital Infections ~ State of the Art ~ Part II.

@en

Rare Orbital Infections ~ State of the Art ~ Part II.

@nl

P1476

Rare Orbital Infections ~ State of the Art ~ Part II.

@en

P2093

Daniel Briscoe

http://www.w3.org/2001/XMLSchema#string

David H Verity

http://www.w3.org/2001/XMLSchema#string

Geoffrey E Rose

http://www.w3.org/2001/XMLSchema#string

Islam AlHashash

http://www.w3.org/2001/XMLSchema#string

Shirin Hamed-Azzam

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Neotropical echinococcosis in Suriname: Echinococcus oligarthrus in the orbit and Echinococcus vogeli in the abdomen.

Survival after rhino-orbital-cerebral mucormycosis in an immunocompetent patient.

Rhinocerebral mucormycosis complicated by internal carotid artery thrombosis in a pediatric patient with type 1 diabetes mellitus: a case report and review of the literature.

Successful treatment of rhino-orbital mucormycosis without exenteration: the use of multiple treatment modalities.

Tuberculous osteomyelitis and optic neuritis.

Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes.

Orbital tuberculosis in childhood.

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.

Posaconazole as salvage therapy for zygomycosis.

P304

183-190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/JOVR.JOVR_202_17

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29719648

http://www.w3.org/2001/XMLSchema#string

P932

5905313

http://www.w3.org/2001/XMLSchema#string